登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由山西白求恩医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06850285,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
15 岁 至 80 岁;性别:不限
登记记录的入选字段
Received Anti-CD30 Ab therapy within 4 weeks before enrollment;
排除标准第 5 条
Unresolved > Grade 1 non-hematologic toxicity associated with any prior treatments;
排除标准第 6 条
ECOG performance status 0-2,KPS>60%;
入选标准第 8 条
At least 1 measurable lesion can be measured according to theLugano 2014 evaluation criteria;
入选标准第 4 条
Hepatitis B(HBsAg、HBsAb、HBeAg、HBeAb、HBcAb),Hepatitis C(Anti-HCV),Anti-HIV Ⅰ/Ⅱ and anti-TP positive(Hepatitis B DNA test is negative except);
排除标准第 3 条
Pregnant or lactating women, and women who have a pregnancy plan within six months;
排除标准第 2 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06850285,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age≥15 years and ≤80years,female and male; CD30+ lymphocyte malignancies; CD30 expression >10% by immunohistochemistry; At least 1 measurable lesion can be measured according to theLugano 2014 evaluation criteria; Not suitable for autologous hematopoietic stem cell transplantation or recurrence after autologous hematopoietic stem cell transplantation; Not suitable for BV treatment or relapse after BV treatment, and the expression of CD30 was confirmed by histology; The estimated survival time ≥3 months; ECOG performance status 0-2,KPS>60%; Sufficient organ function:ALT,AST≤2.5×ULN,patients with liver invasion can be relaxed to ≤ 5 x ULN;serum total bilirubin<34 μmol/L;creatinine clearance rate>30 mL/min;EF≥40%;No pericardial effusion and obvious arrhythmia;SpO2≥92%; ALC ≥0.5×109/L,PLT>30×109/L,Hb>80 g/L and subjects had apheresis venous access and no contraindications for blood cell separation; MRI showed no central involvement of lymphoma; Patients with fertility must be willing to be able to use reliable contraceptive measures ; The subject or legal guardian can understand and voluntarily sign the written informed consent.排除标准:Exclusion Criteria:
Lymphoma-associated hemophagic cell syndrome; Pregnant or lactating women, and women who have a pregnancy plan within six months; Hepatitis B(HBsAg、HBsAb、HBeAg、HBeAb、HBcAb),Hepatitis C(Anti-HCV),Anti-HIV Ⅰ/Ⅱ and anti-TP positive(Hepatitis B DNA test is negative except); Suffered from other malignant tumors, except for for skin basal cell carcinoma, skin squamous cell carcinoma and cervical carcinoma in situ undergoing the radical treatment; Received Anti-CD30 Ab therapy within 4 weeks before enrollment; Unresolved > Grade 1 non-hematologic toxicity associated with any prior treatments; Active uncontrolled bleeding or a known bleeding diathesis; Autologous hematopoietic stem cell transplantation was performed within 6 weeks; Uncontrollable active bacterial or fungal infection; Known allergy to the study drug and its components; Suffer from active autoimmune diseases that require systemic treatment ; Persons with mental or mental illness who cannot cooperate with treatment and efficacy evaluation; Participated in other clinical studies within 1 months prior to this study; History of allogeneic hematopoietic stem cell transplantation; patients with any condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject.
引自 ClinicalTrials.gov, NCT06850285, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06850285,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。